Ipstyl Autogel (Lanreotide)

Lanreotide binds selectively to somatostatin receptors SSTR2 and SSTR5 on endocrine cells. This binding blocks adenylate cyclase, reduces cyclic AMP formation, and suppresses the release of growth hormone, insulin‑like growth factor‑1, and various gastrointestinal hormones, thereby modulating disease‑related hormone excess.

The dosing regimen for Ipstyl Autogel is individualized and determined by the prescribing physician based on the patient’s condition, disease severity, and response to therapy. Healthcare professionals adjust the dose and injection interval according to clinical guidelines and patient monitoring.

Safety data for lanreotide in pregnancy are limited, and the product should only be used if the potential benefit justifies the potential risk to the fetus. During breastfeeding, the drug may be excreted in milk; therefore, it is generally avoided unless the therapeutic advantage outweighs possible risks to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

The primary alternative to lanreotide is octreotide, another somatostatin analog. Both agents suppress similar hormones, but lanreotide is typically administered as a long‑acting gel every 4–8 weeks, whereas octreotide may require more frequent dosing (monthly depot or daily injections). Choice depends on patient preference, tolerability, and specific clinical considerations.

Ipstyl Autogel should be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the gel. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

The medication is supplied as a pre‑filled autogel syringe for subcutaneous injection. A healthcare professional injects the gel into the subcutaneous tissue, typically in the abdomen or thigh, following aseptic technique. The injection site should be rotated to minimize local reactions.

Serious adverse events include gallstone formation, acute pancreatitis, severe hypersensitivity reactions (including anaphylaxis), marked hyperglycaemia or new‑onset diabetes, and cardiac arrhythmias. Patients should be monitored for abdominal pain, jaundice, signs of infection, and any sudden changes in blood glucose or heart rhythm.

Ipstyl Autogel is contraindicated in patients with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is advised for individuals with severe gallbladder disease, uncontrolled diabetes, significant cardiac conduction abnormalities, or those receiving other somatostatin analogs without medical supervision.